Phase 1 double-blind placebo-controlled trial of three divided IV doses of nizaracianine in healthy volunteers

Phase 1, double-blind trial of nizaracianine triflutate in ureteral injury (2 arms), sponsored by Curadel Surgical Innovations, Inc. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Concomitant medication and 3 more. Started Nov 2022; status: active, not recruiting.